UK researchers have developed a single blood test that not only detects antibodies but also measures other signs of an immune system response to the virus, Reuters news agency reported on Tuesday.
This is reportedly useful as not everyone produces measurable amounts of COVID-19 antibodies after infection or vaccination.
Specifically, the blood test measures T cells, powerful immune cells that learn to recognise the virus either after encountering it during infection or through vaccination.
As a part of the new test, blood samples are exposed to replicas of small pieces of the virus. If the T cells in the blood sample recognise these pieces, they are triggered to produce molecules that can be easily measured, such as the inflammatory protein interferon-gamma.
Martin Scurr of Cardiff University School of Medicine, co-author of a report published in Immunology, stated: "The test is very sensitive and seems to be accurate," adding that the test is easy to employ and should play a very useful role in monitoring antibody and T cell responses to the virus.
"However, it remains to be determined what level of antibody and T cell response against the virus might protect from future infection and COVID-19," Scurr also stated.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins